Nesfatin-1 Levels Predict Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction.

• DOI: 10.6515/acs.202007_36(4).20200207a
• Publication Date: 2020-07-01
• Authors: Serkan Sivri; Erdoğan Sökmen; Mustafa Çelık; Kenan Güçlü
• Keywords: Pathogenesis; No reflow phenomenon

Nesfatin-1 is a novel peptide possessing pleiotropic metabolic effects. No-reflow phenomenon (NR) poor prognostic indicator occurring in around 30% of all patients undergoing primary percutaneous coronary interventions (pPCI). Inflammation and complexity artery disease (CAD) play pivotal roles the pathogenesis NR. In this study, we investigated relationship between admission serum nesfatin-1 level, NR CAD assessed by SYNTAX-1 (SS-1) SYNTAX-2 (SS-2) scores with ST-segment elevation myocardial infarction (STEMI) pPCI.